Breaking News Instant updates and real-time market news.

MNK

Mallinckrodt

$36.45

-0.35 (-0.95%)

, ANIP

ANI Pharmaceuticals

$51.16

0.01 (0.02%)

06:25
09/13/17
09/13
06:25
09/13/17
06:25

Mallinckrodt downgraded to Neutral on competitive headwinds at Mizuho

As previously reported, Mizuho downgraded Mallinckrodt (MNK) to Neutral from Buy and slashed its price target to $40 from $70. Following the unexpectedly negative Inomax District Court decision. Analyst Irina Koffler said Mallinckrodt consists of a gradually declining generics portfolio, and a "basket" of branded assets that face some degree of competition and downside risks. Koffler lowered his Inomax forecast to reflect a second market entrant and sees risk to Arthar from any positive progress by competitor ANI Pharmaceuticals (ANIP).

MNK

Mallinckrodt

$36.45

-0.35 (-0.95%)

ANIP

ANI Pharmaceuticals

$51.16

0.01 (0.02%)

MNK Mallinckrodt
$36.45

-0.35 (-0.95%)

09/06/17
CANT
09/06/17
NO CHANGE
Target $52
CANT
Overweight
Mallinckrodt court decision 'not that bad,' says Cantor
In a research note yesterday afternoon titled "Just Breathe, Inomax News Is Not That Bad, In Our View," Cantor Fitzgerald analyst Louise Chen said she remains positive on shares of Mallinckrodt after speaking with management. Inomax still maintains other patents not related to yesterday's court decision, Chen wrote. She adds that Praxair is "not going to be marketed as a directly substitutable product and does not have approval yet." The analyst keeps an Overweight rating on Mallinckrodt with a $52 price target. Morgan Stanley this morning downgraded Mallinckrodt to Equal Weight.
09/06/17
ADAM
09/06/17
NO CHANGE
Target $77
ADAM
Buy
Mallinckrodt Inomax concerns overblown, says Canaccord
Canaccord analyst Dewey Steadman said Mallincrodt's (MNK) selloff following the disappointing litigation result was overblown. He said Inomax represents one of the company's more durable franchises and doesn't see an imminent Praxair (PX) launch. He also believes if Praxair was to launch its competitor drug, he believes the two companies can share the market. Steadman added that Mallinckrodt's valuation is now attractively low and reiterated his Buy rating and $77 price target on the shares.
09/06/17
09/06/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. HP Enterprise (HPE) downgraded to Underperform from Neutral at BofA/Merrill with analyst Wamsi Mohan citing fiscal 2018 headwinds that include increased investment, a competitive pricing environment, and higher commodity costs. 2. Marathon Petroleum (MPC) downgraded to Market Perform from Outperform at Wells Fargo with analyst Roger Read saying he now expects the incentive distribution rights buyout may be at the lower end of the prior 15-20 times range. 3. Verifone (PAY) downgraded to Neutral from Buy at Northcoast with analyst Keith Housum saying he has reduced confidence in the company's ability to grow revenues and increase profitability given the delay in reaching the point of sale market with its new Carbon and Engage platform compared to initial expectations. 4. Mallinckrodt (MNK) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst David Risinger saying he believes yesterday's unfavorable district court ruling in Mallinckrodt's suit against Praxair (PX) has increased the risk of an Inomax generic potentially as soon as October 2018, compared to his prior expectation of 2031. 5. BHP Billiton (BHP) downgraded to Underperform from Neutral at Exane BNP Paribas. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/13/17
MZHO
09/13/17
DOWNGRADE
MZHO
Neutral
Mallinckrodt downgraded to Neutral from Buy at Mizuho
ANIP ANI Pharmaceuticals
$51.16

0.01 (0.02%)

02/22/17
ROTH
02/22/17
DOWNGRADE
Target $69
ROTH
Neutral
ANI Pharmaceuticals downgraded to Neutral from Buy at Roth Capital
Roth Capital analyst Scott Henry downgraded ANI Pharmaceuticals to Neutral from Buy, with a $69 price target, as he awaits 2017 financial guidance. The analyst has near-term concerns with the recent market share decline for the EEMT franchise. However, he notes that the long-term prospects remain more focused on the emergence of corticotropin as a material revenue generator.
03/03/17
ROTH
03/03/17
NO CHANGE
Target $56
ROTH
Neutral
ANI Pharmaceuticals price target lowered to $56 from $69 at Roth Capital
Roth Capital analyst Scott Henry lowered his price target for ANI Pharmaceuticals to $56 from $69 after the company reported Q4 earnings that were within expectations, but 2017 guidance below his targets. With multiple new product launches already underway, the analyst targets the next incremental levers as potential acquisitions in 2017 and corticotropin updates that appear a late 2017/early 2018 event. He reiterates a Neutral rating on the shares.
07/31/17
ADAM
07/31/17
INITIATION
Target $60
ADAM
Buy
ANI Pharmaceuticals initiated with a Buy at Canaccord
Canaccord Genuity analyst Dewey Steadman started ANI Pharmaceuticals with a Buy rating and $60 price target. The company's launch pipeline is strong and could drive "significant near-term growth," the analyst contends.

TODAY'S FREE FLY STORIES

NUS

Nu Skin

$70.84

0.85 (1.21%)

05:11
01/23/18
01/23
05:11
01/23/18
05:11
Recommendations
Nu Skin analyst commentary  »

Nu Skin price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Feb

NFLX

Netflix

$227.58

7.12 (3.23%)

05:08
01/23/18
01/23
05:08
01/23/18
05:08
Recommendations
Netflix analyst commentary  »

Netflix price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

NTR

Nutrien

$53.07

0.07 (0.13%)

05:05
01/23/18
01/23
05:05
01/23/18
05:05
Upgrade
Nutrien rating change  »

Nutrien upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 06

    Feb

NFLX

Netflix

$227.58

7.12 (3.23%)

05:01
01/23/18
01/23
05:01
01/23/18
05:01
Recommendations
Netflix analyst commentary  »

Netflix price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

ADBE

Adobe

$197.84

2.11 (1.08%)

05:00
01/23/18
01/23
05:00
01/23/18
05:00
Recommendations
Adobe analyst commentary  »

Adobe price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

ATUS

Altice USA

$21.90

0.6 (2.82%)

, ALLVF

Altice NV

$11.35

0.3675 (3.35%)

04:58
01/23/18
01/23
04:58
01/23/18
04:58
Upgrade
Altice USA, Altice NV rating change  »

Altice USA upgraded to…

ATUS

Altice USA

$21.90

0.6 (2.82%)

ALLVF

Altice NV

$11.35

0.3675 (3.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$227.58

7.12 (3.23%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Recommendations
Netflix analyst commentary  »

Netflix price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

ALLVF

Altice NV

$11.35

0.3675 (3.35%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Upgrade
Altice NV rating change  »

Altice NV upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
Wolfe Research utilities analyst to hold a luncheon meeting »

Senior Utilities Analyst…

RHT

Red Hat

$128.01

2.07 (1.64%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
Red Hat participates in a conference call with Bernstein »

U.S. SMID-Cap Software…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 06

    Feb

CAMP

CalAmp

$23.13

0.02 (0.09%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
CalAmp has a conference call hosted by JPMorgan »

JPMorgan Analyst Coster…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

AYR

Aircastle

$24.23

-0.03 (-0.12%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
Aircastle management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

CRNCY

Cairn Energy

$6.15

0.11 (1.82%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
Cairn Energy management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

SRE

Sempra Energy

$105.05

-0.94 (-0.89%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
Sempra Energy management to meet with Wolfe Research »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

TRN

Trinity Industries

$36.51

-0.15 (-0.41%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
Trinity Industries management to meet with Wedbush »

Meeting with CFO Perry…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

EPE

EP Energy

$2.48

0.17 (7.36%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
EP Energy to hold a conference call »

Management discusses its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

CQH

Cheniere Energy Partners LP

$28.50

0.28 (0.99%)

, CQP

Cheniere Energy Partners

$30.89

0.41 (1.35%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
Morgan Stanley to hold a tour »

Annual Morgan Stanley…

CQH

Cheniere Energy Partners LP

$28.50

0.28 (0.99%)

CQP

Cheniere Energy Partners

$30.89

0.41 (1.35%)

ENLC

EnLink Midstream

$19.25

0.5 (2.67%)

ENLK

EnLink Midstream Partners

$18.08

0.63 (3.61%)

EPD

Enterprise Products

$29.40

0.74 (2.58%)

NBLX

Noble Midstream

$56.22

1.12 (2.03%)

PAA

Plains All American

$23.05

0.56 (2.49%)

SHLX

Shell Midstream

$30.46

0.33 (1.10%)

TRGP

Targa Resources

$51.00

0.27 (0.53%)

WES

Western Gas Partners

$53.74

1.43 (2.73%)

WGP

Western Gas Equity

$41.91

1.49 (3.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 07

    Feb

  • 16

    Feb

  • 20

    Feb

  • 26

    Feb

BPL

Buckeye Partners

$55.97

0.95 (1.73%)

, CEQP

Crestwood Equity

$28.50

0.75 (2.70%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
UBS to hold a tour »

Houston Winter MLP &…

BPL

Buckeye Partners

$55.97

0.95 (1.73%)

CEQP

Crestwood Equity

$28.50

0.75 (2.70%)

ENLC

EnLink Midstream

$19.25

0.5 (2.67%)

ENLK

EnLink Midstream Partners

$18.08

0.63 (3.61%)

EPD

Enterprise Products

$29.40

0.74 (2.58%)

PAA

Plains All American

$23.05

0.56 (2.49%)

SEP

Spectra Energy Partners

$43.40

0.81 (1.90%)

SHLX

Shell Midstream

$30.46

0.33 (1.10%)

TRGP

Targa Resources

$51.00

0.27 (0.53%)

WES

Western Gas Partners

$53.74

1.43 (2.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 07

    Feb

  • 09

    Feb

  • 16

    Feb

  • 20

    Feb

  • 26

    Feb

SIG

Signet Jewelers

$55.87

0.8 (1.45%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
Signet Jewelers management to meet with Buckingham »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

BNED

Barnes & Noble Education

$7.71

0.01 (0.13%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
Barnes & Noble Education management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

FCPT

Four Corners Property Trust

$24.13

0.45 (1.90%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
Four Corners Property Trust management to meet with JMP Securities »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

PRQR

ProQR Therapeutics

$3.03

0.025 (0.83%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
ProQR Therapeutics to h old an investor event »

Investor Event will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 19

    Feb

BRG

Bluerock Residential

$9.22

0.03 (0.33%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
Bluerock Residential management to meet with JMP Securities »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

UNF

UniFirst

$171.15

0.2 (0.12%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
UniFirst management to meet with Northcoast »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

ABEO

Abeona Therapeutics

$14.85

0.25 (1.71%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
Abeona Therapeutics management to meet with RBC Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.